Breaking News

What good is an opinion section?

November 5, 2023
Editor, First Opinion

Earlier this week, I made an appeal on Twitter/X (sigh) and Bluesky, asking people to name opinion pieces that stood out to them. I periodically teach workshops for academics, wonks, and other experts on how to write for the public, and I was looking to refresh my list of examples of what to do and, perhaps more importantly, what not to do to write engaging, persuasive pieces for general-interest readers.

I received some good suggestions (and am still looking for more—send me your favorites!). But the most thought-provoking response came from Michael J. Socolow, a media historian with the University of Maine: "Interesting question. My answer? None. Since @nytopinion retired the 'Op ed' in favor of 'Guest Essays' I can't think of an essay published that I found sufficiently surprising, counter-intuitive, and persuasive to force me to reconsider an opinion. (It used to happen)," he tweeted

It's an argument he made in Reason in 2021, when the New York Times opinion page officially embraced the grating term "guest essay." In that piece, he traces the history of the New York Times op-ed page, which debuted Sept. 21, 1970. (In my head, the Earth, Wind, & Fire jam "September," which is a fall highlight of my weekly Motown Movement dance exercise class, will henceforth be about op-eds. I just have to change the lyric "Do you remember/ The 21st night of September" to "The 21st morn of September.") 

The op-ed page, Socolow writes, "attempted to render the bitter divisions of the 1960s in text and image on newsprint. It emerged during an era of remarkable innovation and experimentation in U.S. media." Part of that rendering was to capture the worst of the worst: "In its first two decades, the op-ed page fearlessly printed essays that were unquestionably offensive, dehumanizing, and even occasionally vile." That included a 1978 op-ed defending Pol Pot

Today, however, op-eds in the New York Times and elsewhere tend to argue for policies and perspectives that reinforce what the readers — and, let's be honest, the editors — already believe.

And, as an opinion editor who believes in the genre, I get that. Publishing an op-ed that my colleagues and peers disagree with is tough. Nevertheless, I want to do it, and I want to do it more. I don't want to publish the vile — I will not publish the 2020s medical industry equivalent of defending Pol Pot. I don't even want to think about what that might be.

But I do want to publish First Opinions that challenge readers. That means avoiding those essays that preach to the choir — yes, we all want lower drug prices and more equity in the health care system! — in favor of those that say something new, maybe even something they have a strong negative reaction to initially. Ideally, someone you respect should disagree with the argument you're making, or at least say "I never thought of it that way before."

This is about keeping things interesting, of course. But there's more to it than that. I want to provoke discussion and force people to think more deeply about their knee-jerk beliefs by having experts make well-supported arguments. (One example of that: a piece I ran earlier this year asking whether we're talking too much about the teen mental health crisis.) I also think that sometimes op-eds offer a way for us to get prominent people on the record with bad opinions. This doesn't mean I think it's OK to publish something sloppy and overheated for the sake of clicks, of course. But I do think there is value in sharing unpopular good-faith arguments.

When an unpopular op-ed goes viral, opinion editors are often eviscerated online. But I think those angry readers misunderstand something. Op-eds are not — and this needs to be said — editorials. Sometimes the two words are used interchangeably, even by people who are media savvy. But they are distinct: The op-ed is the opinion of the signed author, and an editorial is the opinion of a publication's editorial board. At STAT, we don't have an editorial board. Every opinion is clearly marked as such, with the author's name, affiliation, and any conflicts of interest disclosed. 

I want First Opinion to harken back to the original spirit of the op-ed as a form. So what's your unpopular but strongly held opinion? Submit it to me

Better yet: I want more debates. Are you an expert in your field who disagrees with someone you respect on an important issue? Do the two of you want to debate it publicly, going back and forth two or three times each? Email me, I beg of you. 

This very busy First Opinion featured a whole lot of surprising and thought-provoking ideas, none of them vile or dull: In a heartbreaking first-person essay, Mara Buchbinder — who coined the phrase "patient in waiting" — writes about how her husband is now a new kind of patient in waiting: A liquid biopsy suggests his cancer may be coming back. But for now, all they can do is wait. How effective are celebrity vaccine campaigns? Convincing people to buy medical insurance by telling them it's in their economic interest doesn't seem to work very well. An attempt to keep drug prices down could hurt patients with cystic fibrosis in Colorado. There might be a way to promote Medicaid re-enrollment and improve graduate medical education. Physician-scientist Vivian Cheung, who has a rare disease, proposes a way for the U.S. government to help lower gene therapy prices. Ed Bisch, who lost his son to OxyContin 20 years ago, reflects on the horror of "The Fall of the House of Usher" and its fictional depiction of the Sackler family. Medical providers need more tools to help patients during extreme heat. And on the "First Opinion Podcast": I chatted with Michael H. Bernstein about the placebo effect, the nocebo effect, and my favorite episode of "Freaks & Geeks."  

Recommendation of the week: My book/longform reading, podcast-listening, and movie/TV watching are in a serious slump right now! What are you enjoying? Please share!

Illustration: STAT; Screen capture

Do celebrity vaccine endorsements like Travis Kelce's actually change behavior?

Selling health is not the same as selling shoes. That makes using famous people to pitch medical products much trickier.

By Christopher Morse


Liquid biopsy for cancer recurrence creates a new kind of patient-in-waiting

When a test to predict my husband's cancer recurrence came back positive, there was only one thing we could do: wait.

By Mara Buchbinder


I lost my son to OxyContin. 'The Fall of the House of Usher' is my Sackler revenge fantasy

I lost my son to Oxycontin. "The Fall of the House of Usher" is my (and many others') Sackler revenge fantasy.

By Ed Bisch



Illustration: STAT; Source: Business Wire/AP

State Prescription Drug Affordability Boards could end up limiting access to the life-saving cystic fibrosis medication Trikafta

Access to Trikafta is now at risk for several hundred people with cystic fibrosis, thanks to what some might consider to be good intentions.

By Gunnar Esiason


The best way to convince healthy people to get insurance is not 'because it's in your financial interest'

One-fifth of uninsured adults say they don't need or want insurance. Here's how to persuade them to buy it anyway.

By Wendy Netter Epstein and Christopher T. Robertson


Let's leverage graduate medical education to increase Medicaid re-enrollment

Funding graduate medical education primarily through Medicare is the flaw at the heart of our expensive health care system.

By Abraham Nussbaum and Renee Y. Hsia


Listen: Sniffing out the power, and limits, of the placebo effect

"If we expect to feel better, then we probably will," says Michael H. Bernstein, an expert on the placebo effect and the nocebo effect.

By Torie Bosch


STAT+ | How the government can help lower the price — not just the cost — of cutting-edge gene therapies

The high cost of gene therapies doesn't just limit access to these medicines — it also stunts work toward future cures and treatments.

By Vivian G. Cheung


Health care providers need help to treat patients during extreme heat events

We must ensure health care providers understand the critical role they can play and have the resources they need during extreme heat.

By Julie Varughese and Caleb Dresser


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying First Opinion? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments